Cullinan Therapeutics, Inc. (CGEM)

Cullinan Therapeutics Statistics

Total Valuation

CGEM has a market cap or net worth of $850.58 million. The enterprise value is $501.08 million.

Market Cap	850.58M
Enterprise Value	501.08M

Important Dates

The last earnings date was Thursday, May 7, 2026, before market open.

Earnings Date	May 7, 2026
Ex-Dividend Date	n/a

Share Statistics

CGEM has 61.46 million shares outstanding. The number of shares has increased by 2.94% in one year.

Current Share Class	61.46M
Shares Outstanding	61.46M
Shares Change (YoY)	+2.94%
Shares Change (QoQ)	+2.13%
Owned by Insiders (%)	1.09%
Owned by Institutions (%)	80.25%
Float	44.27M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.32
P/TBV Ratio	2.32
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 10.28, with a Debt / Equity ratio of 0.01.

Current Ratio	10.28
Quick Ratio	10.09
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -48.16% and return on invested capital (ROIC) is -957.81%.

Return on Equity (ROE)	-48.16%
Return on Assets (ROA)	-30.57%
Return on Invested Capital (ROIC)	-957.81%
Return on Capital Employed (ROCE)	-65.34%
Weighted Average Cost of Capital (WACC)	3.75%
Revenue Per Employee	n/a
Profits Per Employee	-$2.03M
Employee Count	109
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +75.86% in the last 52 weeks. The beta is -0.09, so CGEM's price volatility has been lower than the market average.

Beta (5Y)	-0.09
52-Week Price Change	+75.86%
50-Day Moving Average	14.20
200-Day Moving Average	10.81
Relative Strength Index (RSI)	43.78
Average Volume (20 Days)	955,931

Short Selling Information

The latest short interest is 8.80 million, so 14.32% of the outstanding shares have been sold short.

Short Interest	8.80M
Short Previous Month	8.11M
Short % of Shares Out	14.32%
Short % of Float	19.87%
Short Ratio (days to cover)	12.54

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-240.35M
Pretax Income	-221.04M
Net Income	-221.04M
EBITDA	-240.04M
EBIT	-240.35M
Earnings Per Share (EPS)	-$3.72

Balance Sheet

The company has $351.89 million in cash and $2.38 million in debt, with a net cash position of $349.50 million or $5.69 per share.

Cash & Cash Equivalents	351.89M
Total Debt	2.38M
Net Cash	349.50M
Net Cash Per Share	$5.69
Equity (Book Value)	366.17M
Book Value Per Share	5.96
Working Capital	326.25M

Cash Flow

In the last 12 months, operating cash flow was -$178.64 million and capital expenditures -$49,000, giving a free cash flow of -$178.69 million.

Operating Cash Flow	-178.64M
Capital Expenditures	-49,000
Depreciation & Amortization	314,000
Net Borrowing	n/a
Free Cash Flow	-178.69M
FCF Per Share	-$2.91

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CGEM does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.94%
Shareholder Yield	-2.94%
Earnings Yield	-25.99%
FCF Yield	-21.01%

Analyst Forecast

The average price target for CGEM is $31.45, which is 127.24% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$31.45
Price Target Difference	127.24%
Analyst Consensus	Strong Buy
Analyst Count	12
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-19.72%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1